Guhathakurta, Debarpan http://orcid.org/0000-0001-6475-6366
Petrušková, Aneta
Akdaş, Enes Yağız
Perelló-Amorós, Bartomeu
Frischknecht, Renato
Anni, Daniela http://orcid.org/0000-0002-5825-6303
Weiss, Eva-Maria
Walter, Martin http://orcid.org/0000-0001-7857-4483
Fejtová, Anna http://orcid.org/0000-0002-1815-4409
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB779/A06)
Article History
Received: 20 April 2023
Revised: 21 December 2023
Accepted: 8 January 2024
First Online: 22 January 2024
Competing interests
: MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors report no biomedical financial interests or other potential conflicts of interest.